Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults....
People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an
autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and
bendamustine.
The clinical evidence is from a small study that did not directly compare tafasitamab plus
lenalidomide with any other trea...
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Commercial arrangement
There is a simple discount patient access scheme for eptinezumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact United...
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Commercial arrangement
There is a managed access agreement, which includes a patient access scheme, for trastuzumab derux...
Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.
Commercial arrangements
There is a simple discount patient access scheme for lenvatinib and a commercial access agreement for pembrolizumab. NHS organisations can g...